Isracann Biosciences Inc. (ISCNF) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ISCNF representa a Isracann Biosciences Inc., una empresa del sector Healthcare con un precio de $ (capitalización de mercado 0). Calificado con 48/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.
Ultimo analisis: 16 mar 2026Isracann Biosciences Inc. (ISCNF) Resumen de Asistencia Médica y Tuberías
Isracann Biosciences Inc. focuses on the cultivation and distribution of medical cannabis within Israel, with exports to Germany. Operating in the Drug Manufacturers - Specialty & Generic industry, the company develops cultivation facilities to support its operations and navigate the evolving regulatory environment of the medical cannabis market.
Tesis de Inversión
Isracann Biosciences Inc. presents a speculative investment opportunity within the evolving medical cannabis market. The company's focus on cultivation and distribution in Israel, coupled with exports to Germany, offers exposure to growing markets. However, the company's market capitalization of $0.00B and negative P/E ratio of -0.47 indicate financial challenges. Potential investors should carefully consider the risks associated with OTC-listed companies, including liquidity and disclosure requirements. Growth catalysts include expansion of cultivation facilities and increased market penetration in Germany. The company's beta of 0.19 suggests lower volatility compared to the overall market.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market capitalization of $0.00B, reflecting the company's small size and potential for growth or volatility.
- Negative P/E ratio of -0.47, indicating that the company is currently not profitable.
- Beta of 0.19, suggesting the stock is less volatile than the overall market.
- Focus on the medical cannabis market in Israel, a region with evolving regulations and increasing demand.
- Exports to Germany, providing access to a larger and more established market for medical cannabis.
Competidores y Pares
Fortalezas
- Cultivation and distribution expertise in Israel.
- Export agreements to Germany.
- Development of cultivation facilities.
- Focus on the medical cannabis market.
Debilidades
- Small market capitalization.
- Negative P/E ratio.
- Limited financial resources.
- Dependence on regulatory approvals.
Catalizadores
- Upcoming: Expansion of cultivation facilities to increase production capacity.
- Ongoing: Increasing demand for medical cannabis in Israel and Germany.
- Ongoing: Evolving regulations in the cannabis industry creating new market opportunities.
Riesgos
- Potential: Evolving regulations in the cannabis industry could negatively impact operations.
- Potential: Competition from established pharmaceutical companies and other cannabis producers.
- Ongoing: Limited financial resources may hinder growth initiatives.
- Ongoing: Dependence on regulatory approvals for cultivation and distribution.
Oportunidades de crecimiento
- Expansion of cultivation facilities: Isracann can increase its production capacity by expanding its cultivation facilities within Israel. This expansion would allow the company to meet increasing demand in both the domestic and export markets. The global medical cannabis market is projected to reach $55 billion by 2026, providing a significant opportunity for growth. Timeline: Ongoing.
- Increased market penetration in Germany: Isracann can increase its sales and market share in Germany by establishing partnerships with distributors and pharmacies. The German medical cannabis market is one of the largest in Europe, offering significant potential for revenue growth. The timeline for this growth is dependent on regulatory approvals and market access. Market size: Estimated at $2 billion by 2026.
- Development of new cannabis-based products: Isracann can invest in research and development to create new medical cannabis products, such as oils, creams, and edibles. These new products can cater to a wider range of patient needs and preferences, increasing the company's revenue streams. The market for cannabis-based products is growing rapidly, driven by increasing consumer demand. Timeline: 2-3 years.
- Strategic partnerships and acquisitions: Isracann can pursue strategic partnerships or acquisitions to expand its market reach and product offerings. These partnerships can provide access to new technologies, distribution networks, and markets. The cannabis industry is consolidating, creating opportunities for strategic alliances and acquisitions. Timeline: Ongoing.
- Focus on research and development: Isracann can invest in research and development to improve its cultivation techniques and develop new cannabis strains with specific medicinal properties. This focus on innovation can differentiate the company from its competitors and attract patients seeking specialized treatments. The market for specialized medical cannabis products is growing, driven by increasing awareness of the therapeutic benefits of cannabis. Timeline: Ongoing.
Oportunidades
- Expansion of cultivation facilities.
- Increased market penetration in Germany.
- Development of new cannabis-based products.
- Strategic partnerships and acquisitions.
Amenazas
- Evolving regulations in the cannabis industry.
- Competition from established pharmaceutical companies.
- Fluctuations in cannabis prices.
- Changes in consumer preferences.
Ventajas competitivas
- Established cultivation facilities in Israel.
- Distribution network in Israel.
- Export agreements with distributors in Germany.
- Expertise in cultivating medical cannabis.
Acerca de ISCNF
Isracann Biosciences Inc., established in 2010 and headquartered in Vancouver, Canada, is dedicated to the cultivation and distribution of medical cannabis, primarily within Israel. Originally named Atlas Blockchain Group Inc., the company rebranded in October 2019 to reflect its focus on the burgeoning cannabis industry. Isracann develops cultivation facilities to ensure a consistent and high-quality supply of medical cannabis. The company also exports its products to Germany, expanding its market reach beyond Israel. Isracann operates in a sector characterized by evolving regulations and increasing demand for medical cannabis products. The company's strategic focus on cultivation and distribution positions it to capitalize on the expanding market for medical cannabis in both Israel and Europe.
Qué hacen
- Cultivates medical cannabis in Israel.
- Distributes medical cannabis products.
- Develops cultivation facilities to increase production capacity.
- Exports medical cannabis products to Germany.
- Focuses on the medical cannabis market.
- Adapts to evolving regulations in the cannabis industry.
Modelo de Negocio
- Cultivation of medical cannabis.
- Distribution of cannabis products to pharmacies and distributors.
- Export of cannabis products to international markets.
- Revenue generation through sales of medical cannabis products.
Contexto de la Industria
Isracann Biosciences Inc. operates within the Drug Manufacturers - Specialty & Generic industry, specifically targeting the medical cannabis market. This sector is characterized by rapid growth, evolving regulations, and increasing acceptance of cannabis for medical purposes. The competitive landscape includes both established pharmaceutical companies and emerging cannabis producers. Isracann's focus on cultivation and distribution in Israel positions it to capitalize on the local market, while exports to Germany provide access to a larger European market. The industry is subject to regulatory changes and market fluctuations, requiring companies to adapt to evolving conditions.
Clientes Clave
- Patients requiring medical cannabis for various conditions.
- Pharmacies and distributors in Israel.
- Pharmacies and distributors in Germany.
Finanzas
Gráfico e información
Precio de la acción de Isracann Biosciences Inc. (ISCNF): Price data unavailable
Últimas noticias
-
Stocks That Hit 52-Week Highs On Tuesday
· 24 mar 2020
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para ISCNF.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para ISCNF.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de ISCNF en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Ajay Singh Kaila
CEO
Ajay Singh Kaila serves as the CEO of Isracann Biosciences Inc. His background includes experience in corporate management and strategic development. Prior to joining Isracann, Kaila held various leadership positions in the technology and resource sectors, focusing on driving growth and innovation. He brings a track record of successfully navigating complex regulatory environments and building strong teams. Kaila's expertise in strategic planning and execution is expected to guide Isracann through its next phase of growth in the medical cannabis market.
Historial: Since assuming the role of CEO, Ajay Singh Kaila has focused on expanding Isracann's cultivation capacity and strengthening its distribution network. He has overseen the development of new cultivation facilities and the expansion of the company's export operations to Germany. Kaila has also prioritized building relationships with key stakeholders in the medical cannabis industry, including regulators, distributors, and researchers.
Información del mercado OTC de ISCNF
The OTC Other tier represents the lowest tier of the OTC market, indicating that Isracann Biosciences Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB, or major exchanges like NYSE or NASDAQ. Companies in this tier may have limited trading volume and liquidity. Investing in companies on the OTC Other tier carries significant risks due to the potential for limited information and regulatory oversight compared to companies listed on major exchanges.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited liquidity due to OTC Other listing.
- Lack of regulatory oversight compared to major exchanges.
- Potential for limited financial disclosure.
- Higher volatility due to low trading volume.
- Increased risk of fraud or manipulation.
- Verify the company's financial reporting practices.
- Obtain and review audited financial statements.
- Assess the company's management team and their experience.
- Research the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Company has been in operation since 2010.
- Focus on the medical cannabis market.
- Exports to Germany.
- Development of cultivation facilities.
Lo Que los Inversores Preguntan Sobre Isracann Biosciences Inc. (ISCNF)
¿Cuáles son los factores clave para evaluar ISCNF?
Isracann Biosciences Inc. (ISCNF) actualmente tiene una puntuación IA de 48/100, indicando puntuación baja. Fortaleza clave: Cultivation and distribution expertise in Israel.. Riesgo principal a monitorear: Potential: Evolving regulations in the cannabis industry could negatively impact operations.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de ISCNF?
ISCNF actualmente puntúa 48/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de ISCNF?
Los precios de ISCNF se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre ISCNF?
La cobertura de analistas para ISCNF incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en ISCNF?
Las categorías de riesgo para ISCNF incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Evolving regulations in the cannabis industry could negatively impact operations.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de ISCNF?
La relación P/E para ISCNF compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está ISCNF sobrevalorada o infravalorada?
Determinar si Isracann Biosciences Inc. (ISCNF) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de ISCNF?
Isracann Biosciences Inc. (ISCNF) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Limited information available for OTC-listed companies.
- Financial data may not be readily available or audited.